Diary

  • Mon
    18
    Jan
    2021
    Tue
    19
    Jan
    2021

    10am - 12.30pmOnline, live event


    Format:
    This is a live, virtual event. Each morning’s content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video. The presentations will be available online for 30 days after the live event.

    Description:

    The aim of this course, spread over two mornings, is to provide learners with a good, general understanding of the concepts that underlie precision cancer medicine.

    The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. Elaine will explain how far we are able to do this by exploring the features of cancer we can target now, and where we might get to in the future. She will also look at when precision medicine falls down, and why expectations and realities don’t always align.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50 per morning
    To book, contact: conferenceteam@rmh.nhs.uk
    View the programme for morning 1
    View the programme for morning 2

  • Mon
    26
    Apr
    2021
    Tue
    27
    Apr
    2021

    10am - 1pmOnline, live event

     

    Format: This is a live, virtual event. Each morning’s content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video. The presentations will be available online for 30 days after the live event.

    Description: Over the course of two mornings, Elaine will guide you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
    The first morning’s focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.
    The second morning is about cancer’s relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.
    As ever, Elaine's presentations are full of colourful and enlightening illustrations to help you make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a relatively limited understanding of cell biology are able to understand (if you don't understand the relationship between DNA, genes and proteins, do look this up beforehand).

    View the programme for morning 1

    View the programme for morning 2

    Audience: This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer.

    Cost: £50 per morning; the content will be available for 30 days after the event

    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2921

  • Thu
    08
    Jul
    2021

    10am - 12.30pmOnline, live event


    Description:

    The aim of this morning's course is to provide an up-to-date overview of targeted treatments and immunotherapies given to people with malignant melanoma. This includes treatment combinations and new approaches currently being investigated in clinical trials.

    Elaine's goal is to explain the science that underpins each treatment and to provide learners with a broad understanding of why treatments work well for some patients but not for others.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50
    To book, contact: conferenceteam@rmh.nhs.uk or book online
    View the programme

  • Fri
    09
    Jul
    2021

    10am - 12.30pmOnline, live event


    Description:

    The aim of this morning's course is to provide an up-to-date overview of targeted treatments and immunotherapies given to people with bowel cancer. This includes EGFR-targeted antibodies, B-Raf & MEK inhibitors, immunotherapies, and treatment combinations currently being investigated in clinical trials.

    Elaine's goal is to explain the science that underpins each treatment and to provide learners with a broad understanding of why treatments work well for some patients but not for others.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50
    To book, contact: conferenceteam@rmh.nhs.uk or book online
    View the programme

  • Thu
    09
    Dec
    2021

    10am - 12.30pmOnline, live event


    Description:
    Over the course the morning, Elaine guides you through the scientific concepts that underpin many of the most used targeted cancer treatments for solid tumours.

    Elaine begins by describing what we can and can't target, and the mechanisms of action of monoclonal antibodies and small molecules that block kinases. She then looks at the many treatments that block growth factor controlled signalling pathways. Finally, she turns her attention to other targets and to various biomarker tests to select the right approach for each patient.

    This morning is the first part of a virtual study day. On Friday 10 December it is followed by “Molecular Mechanisms of Immunotherapies for Solid Tumours”.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50
    To book, contact: conferenceteam@rmh.nhs.uk or book online
    View the programme

  • Fri
    10
    Dec
    2021

    10am - 12.30pmOnline, live event


    Description:

    The focus of this morning is on cancer’s relationship with the immune system, and how this knowledge is being used to improve the outlook of people with various solid tumours. Elaine focuses much of her attention on the checkpoint inhibitor group of immunotherapies and highlights some of the lessons learned through the hundreds of clinical trials with checkpoint inhibitors that have taken place over the past decade.

    In the latter part of the morning Elaine looks at other technologies, such as CAR T cell therapy, vaccine-based treatments and oncolytic viruses.

    This morning is the second part of a virtual study day and follows on from “Molecular Mechanisms of Targeted Therapies for Solid Tumours” on Thursday 09 December.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50
    To book, contact: conferenceteam@rmh.nhs.uk or book online
    View the programme